Barry Simon Sells 165,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 165,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

ImmunityBio Stock Up 17.5%

Shares of IBRX traded up $1.72 during mid-day trading on Tuesday, hitting $11.55. 82,882,982 shares of the company traded hands, compared to its average volume of 31,529,002. The company has a market capitalization of $11.38 billion, a PE ratio of -30.39 and a beta of 0.16. The business has a 50 day moving average of $4.82 and a 200 day moving average of $3.24. ImmunityBio, Inc. has a 1-year low of $1.83 and a 1-year high of $12.28.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, research analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors have recently modified their holdings of the stock. Walser Wealth Management Company A Ltd Liability Co purchased a new position in shares of ImmunityBio during the 4th quarter valued at about $59,000. Invesco Ltd. boosted its stake in shares of ImmunityBio by 14.6% in the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock worth $362,000 after buying an additional 23,353 shares during the last quarter. Corient Private Wealth LLC grew its holdings in ImmunityBio by 69.7% during the fourth quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock worth $660,000 after acquiring an additional 136,858 shares during the period. EP Wealth Advisors LLC purchased a new position in ImmunityBio during the fourth quarter valued at approximately $35,000. Finally, Empowered Funds LLC purchased a new position in ImmunityBio during the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler increased their price objective on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. BTIG Research raised their price objective on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research report on Monday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, ImmunityBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.60.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.